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A B S T R A C T
Lymphomas represent the third most common group of cancers in childhood and adolescence, mature B non Hodg-
kin’s lymphoma (B-NHL) accounting for up to 60% of newly diagnosed patients. The diagnosis of specific entities of
B-NHL is based on well-defined morphologic analysis, immunophenotyping, cytogenetics and molecular genetics, which
determine the optimal treatment strategy. In adult population a major turning point in treatment of B-NHL has been
achieved since rituximab, in combination with CHOP has improved the survival rate up to 19%. Rituximab is a chimeric
monoclonal antibody that targets CD20, a transmembrane calcium channel expressed on normal and malignant B-cells
that mediates cytotoxic, apoptotic and anti-proliferative effects. The effect of rituximab in pediatric population is still not
well enough investigated. Based on morphology and immunophenotype of malignant cells, seven children with B-NHL
in our institution were eligible for treatment with modified B-NHL-Berlin-Frankfurt-Münster (BFM)-95-based protocol
with rituximab administered on day -5. The complete remission was achieved in all seven patients. Six patients are still
in complete remission at least 12 months after having finished chemotherapy and one patient relapsed two months after
the last cycle and subsequently died. Major adverse effects observed during treatment were prolonged B-cell depletion
and myelosupression. Rituximab in combination with B-NHL-BFM-95 protocol was otherwise well tolerated and proved
to be effective in children and adolescents with B-NHL. The number of our patients is too small and the follow-up of a
larger group of patients will help in defining the role of rituximab in the treatment of childhood B-NHL.
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Introduction
In pediatric population the mature B cell-non-Hodg-
kin lymphomas (NHL) represent approximately 60% of
all diagnosed NHL, with Burkitt’s lymphoma (BL)/Bur-
kitt’s-like lymphoma (BLL) and diffuse large B-cell lym-
phomas (DLBCL) accounting for up to 40% and 10–20%
of cases, respectively1,2.
The diagnostic criteria for B-NHL according the new
World Health Organization (WHO) classification include
pathology, immunophenotype, cytogenetics and molecu-
lar genetics, which determine the approach to therapy
and prognosis.
During the last decade the 5-year event–free survival
(EFS) of children with both localized and advanced B-
-NHL has improved significantly, mainly due to intensive
multi-agent chemotherapy protocols applied as standard
treatment approach. The EFS for stages I and II now
reaches 90–95% and for stages III and IV 80–90%,
respectively3–5.
In spite of this success, a proportion of patients do not
respond to therapy. High-dose therapy induces toxicity in
a majority of patients, resulting in numerous complica-
tions, increased demand for supportive care and pro-
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longed hospitalization periods5. Patients with relapsed
B-NHL represent an especially vulnerable group, as their
prognosis remains poor despite aggressive therapy ap-
proach, with EFS being 30%6. Therefore, further studies
are needed to optimize the therapeutic approach in this
group of patients.
Rituximab is a chimeric monoclonal antibody target-
ing CD20, a transmembrane calcium channel which is
expressed on all normal B-cells and 98% of malignant
B-NHL cells7. It mediates complement-dependent cytoto-
xicity and antibody-dependent cellular cytotoxicity, sen-
sitizes B-NHL cells to cytotoxic chemotherapy and has
direct apoptotic and anti-proliferative effects8. Due to en-
couraging results obtained from two pivotal trials9,10,
regimen consisting of rituximab and CHOP (cyclophos-
phamide, doxorubicin, vincristine, prednisone) is now
well established as a standard first-line treatment for dif-
fuse large B cell lymphoma (DLBCL) in adult patients
and is a putative viable treatment in patients with re-
lapsed or refractory indolent B-NHL.
Data on combined therapy with rituximab in pediat-
ric population with B-NHL are still scarce and many of
the trials have been published only as abstracts or brief
reports.
The aim of this study was to evaluate the therapeutic
effect and toxicity of the modified B-Non-Hodgkin’s Lym-
phoma (NHL)-Berlin-Frankfurt-Munster (BFM)-95-ba-
sed protocol + rituximab in 7 children with diffuse large
B cell lymphoma (DLBCL), Burkitt (BL) and Burkitt-like
lymphoma (BLL), with emphasis on diagnostic criteria
and molecular characteristics of these entities.
Methods
Patients and eligibility
All patients met the following study criteria: age be-
low 18 years, newly diagnosed with either CD20+ Bur-
kitt or Burkitt-like lymphoma and DLBCL (according to
the Revised European-American Lymphoma Classifica-
tion or the World Health Organization Classification),
stage III or IV according to Ann Harbour staging system,
and stage II if LDH levels were at least two-fold the insti-
tutional upper value; they have not received any previ-
ous treatment; active hepatitis infection had to be ex-
cluded by serologic tests; the patients had to be available
for follow-up for at least two years after beginning of the
therapy. A written informed consent was required from
the patients’ parents.
Diagnosis
The diagnosis was established according to physical
examination, a full blood count (FBC), a metabolic evalu-
ation, chest X-ray scan, a MSCT scan of neck, thorax, ab-
domen and pelvis to evaluate the extent of the spreading
of the disease and staging, a CT brain scan where indi-
cated, a percutaneous sternal bone marrow (BM) aspira-
tion and a lumbar puncture prior to treatment.
All patients underwent surgery to obtain a sample for
histology and radical surgery was performed in two pa-
tients with stage II disease. The diagnosis of B-NHL was
based on both histology and cytology in all cases, includ-
ing PCR and FISH analysis. Fine needle aspiration mate-
rial of bone marrow was air dried and stained for mor-
phological analysis with May-Grünwald-Giemsa (Figures
1 and 2).
The expression of CD20 on lymphoma cells was iden-
tified by immunohistochemistry in all cases. In addition,
in two patients with bone marrow involvement, CD20
positivity was verified by flow cytometry (Figure 3). The
patients in whom specific translocations were identified
were included in the study.
Treatment
All patients received intravenous infusions of rituxi-
mab at a dose of 375 mg/m2 5 days prior to each cycle of
chemotherapy according to the standard NHL-BFM 95
treatment protocol, with a modification of prolonging the
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Fig. 1. Fine needle aspiration material of bone marrow in patient
with B-ALL, stained for morphological analysis with May-
-Grünwald-Giemsa, large magnification. Pathognomonic cytoplas-
matic vacuoles visible inside lymphocytes.
Fig. 2. Fine needle aspiration material of bone marrow in patient
with DLBCL, stained for morphological analysis with May-Grün-
wald-Giemsa, small magnification. Typical morphological
findings.
time interval between the cycles to 28 days. Prior to
rituximab each patient received premedication consist-
ing of paracetamol 15 mg/kg per os and diphenhydramine
1 mg/kg in a slow intravenous infusion.
Rituximab was diluted with 0.9% NaCl and was ad-
ministered for the first time at a speed of 0.5 mg/kg/hour
(max. 50 mg) during the first hour, and was subsequently
increased to 0.5mg/kg with every following hour.
During following cycles of chemotherapy the infusion
started with a dose of 1 mg/kg, and the dose was subse-
quently increased to 1 mg/kg every following hour.
In case of adverse reactions the infusion was stopped
immediately and saline solution was administered. After
30 minutes the rituximab was continued at initial speed.
In the event of more severe reactions or anaphylaxis,
the patient received treatment as for other allergic (ana-
phylactic) reactions. Supportive treatment was adminis-
tered according to NHL-BFM 95 protocol.
Patients’ follow up
Complete remission (CR) was defined by the absence
of tumor mass confirmed by clinical examination and im-
aging methods, normal FBC, BM and cerebrospinal fluid
(CSF) findings. Control MSCT to evaluate tumor regres-
sion was performed after the second cycle of chemother-
apy; in case of complete remission, defined by presence of
less than one third of tumor mass, it was repeated after
the sixth cycle. In case more than one third of tumor
mass remained (i.e. partial remission or non-response);
the MSCT was repeated after the fourth and sixth cycle.
In patients with FAB-L3 ALL the percutaneous ster-
nal (BM) aspiration was performed before second, third
and fourth cycle of chemotherapy.
After completing the treatment, all patients under-
went monthly blood and metabolic evaluation during the
first year, and every three to six months during the sec-
ond year. A control MSCT scan of neck, thorax, abdomen
and pelvis was performed at six, twelve and twenty four
months after having received the last cycle of chemother-
apy and the last is planned after thirty six months.
In patients with leukemia, BM aspiration was per-
formed twelve and eighteen months after completing the
chemotherapy and the last is planned after thirty months.
Results
A total of 7 patients of different sex and age were en-
rolled between November 2006 and December 2007, as
demonstrated in Table 1. The median age was 8 years,
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Fig. 3. Follow-up of CD20+ bone marrow B-cells in patient with
B-ALL detected by flow cytometry at diagnosis, with clear group-
ing in the area typical for B-ALL (A). Absence of CD20+ B-cells
during treatment with rituximab (B). Normalization of CD20+
population of B-cells 12 months after completing the treatment
(C).
TABLE 1
ELIGIBLE PATIENTS FOR TREATMENT WITH MODIFIED B-NHL-BFM-95 PROTOCOL AND RITUXIMAB
Patient Age Diagnosis Primary site Blasts in the bone marrow
BV, male 8 DLBCL, st II nasopharynx 2%
BD, male 6 DLBCL, st II tonsil 1%
BN, female 15.5 DLBCL, st IV abdomen, thorax 2.50%
GS, female 7 DLBCL/L3ALL, st IV,t(8;14) abdomen 83%
MA, male 4 Burkitt-like B-NHL, L3ALL, st IV abdomen, thorax 96%
VM, male 11 BL, L3ALL, st IV abdomen 70%
KA, male 15.5 DLBCL, st IV abdomen, thorax 2%
BL – Burkitt’s lymphoma, BLL – Burkitt’s-like lymphoma, DLBCL – diffuse large B-cell lymphoma
ranging from 4 years to 15,5 years. All the patients were
first diagnosed with B-NHL in our institution, two of
them with DLBCL stage II, two with DLBCL stage IV,
one with DLBCL/L3ALL stage IV, one with BLL/L3ALL
stage IV and one with BL/L3ALL stage IV disease. Two
patients with grade II disease had LDH level higher than
500U/L which is more than two fold the institutional up-
per value and therefore met all the required criteria for
rituximab treatment.
None of the patients had malignant cells in the cere-
brospinal fluid.
Cytogenetic analysis was performed in all patients
and showed translocation t(8;14) in one patient with
DLBCL/L3ALL stage IV disease. Other patients had nor-
mal cytogenetics.
Radical surgery was performed in two patients with
disease stage II localized in tonsils and epipharynx re-
spectively, whereas all other patients underwent surgery
to obtain a tumor sample for histological analysis.
Chemotherapy was initiated directly after recovering
from surgery, usually within one week after admittance
to our institution.
Two patients with stage II disease received 4 cycles of
rituximab and 4 cycles of chemotherapy, respectively.
Five patients with stage IV disease received 6 cycles of
rituximab and 6 cycles of chemotherapy.
Complete remission was achieved in all 7 patients. Six
patients achieved remission before completing the sec-
ond cycle of chemotherapy and only one patient with
DLBCL grade IV achieved remission just before the
fourth cycle of chemotherapy. Six patients are still in
complete remission (19, 22, 23, 25, 26 and 27 months af-
ter completing the treatment).
One patient with DLBCL/L3ALL stage IV suffered a
meningeal relapse two months after having completed
the sixth cycle of chemotherapy; at that time the PCR
analysis of bone marrow aspirate showed clonal rear-
rangement of the IgH gene. The patient was treated ac-
cording to NHL-BFM 1995 protocol and received ritu-
ximab on day –5. An Ommaya reservoir was implanted
for intraventricular therapy. Following chemotherapy,
the radiation of cranium and upper 3 segments of cervi-
cal spine were performed with a total of 2400 cGy. De-
spite the aggressive multi-agent treatment approach, he-
matological dissemination of disease occurred and the
patient died 8 months after the first relapse.
Adverse effects
Mucositis was registered in all patients. Major ad-
verse effects of rituximab therapy were prolonged B-cell
depletion and myelosupression that resulted in severe
disseminated fungal infections and sepsis. This condition
was then treated with amphotericin B or caspofungin
and antibiotics, respectively.
All patients developed fungal infection of oral mu-
cosa, ranging from intense oral thrush to wide spread ex-
cessive infection of oral and esophageal mucosa, dis-
abling any oral intake, as well as maceration and epi-
dermolysis of perigenital area in the most severe cases.
One patient had a transitory loss of intestinal peri-
staltics which was treated conservatively. In one patient
a transitory increase of blood urea and creatinin levels
was noted during the first cycle of chemotherapy, which
subsided spontaneously after completing the treatment.
All patients required blood products due to severe bone
marrow aplasia.
Discussion
The recent REAL and WHO classification suggests
four major subtypes of pediatric NHL: small, non-cleaved
cell (Burkitt and Burkitt’s like), lymphoblastic, B- large
cell lymphoma and anaplastic large cell lymphoma. Ac-
cording to clinical presentation, NHL can be roughly
classified as low-, intermediate- (indolent) and high-grade
(aggressive) tumors.
However the classification includes immunophenoty-
ping and molecular and genetic analysis of tumor tissue,
which erases differences between certain entities in NHL
but it also allows more accurate definition of origin of tu-
mor cells thus steering approach in treatment, targeting
tumor specific antigens by means of a growing number of
selected antibodies. More than 90% of children are diag-
nosed with high grade tumors, whereas low and interme-
diate grade tumors gain in frequency after adolescence.
In adult population approximately 5% of new cases of
invasive cancer diagnosed in the US in 2001 were NHL2,
the indolent type accounting for 25–40%, and the aggres-
sive forms for 60–75%3,4. Almost 90% of all lymphomas
are of B-cell origin however in contrast to pediatric NHL,
the most common forms are follicular B-cell lymphoma,
which is very rare in children, and large B- or T-cell lym-
phoma. In pediatric population 9–10% of all diagnosed
cancers are NHL10, B-cell NHL accounting for up to 60%
of all diagnosed NHL. This difference in immunopheno-
type and histology presumably reflects changes in func-
tion and cellular profiling of the immune system of pedi-
atric and adult patients6.
Although more than 90% of pediatric NHL is of high-
-grade histology, the outcome of treatment is better than
the adult’s and after intensive multiagent chemotherapy
more than 80% of patients achieve long-term EFS8,9,11. In
children with B-NHL the overall EFS at 5 years amounts
to 86±2%11. Boys are affected two to three times more
frequently than girls, with incidence in both sexes stea-
dily increasing throughout life6,10.
During the past 17 years 76 patients were diagnosed
with Non Hodgkin lymphoma in this institution. 31 of
them (40%) were diagnosed with B-cell Non Hodgkin
lymphoma but none with follicular lymphoma. 16 pa-
tients were male and 15 were female, with median age
9.3 years (2–16 years), which stands to some extent in
discordance with general statistics for childhood B-NHL.
Following the encouraging results reported from trea-
tment of adult NHL with rituximab in combination with
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CHOP, seven patients in this institution were chosen for
the first time for treatment with NHL-BFM95 protocol
and rituximab.
In pivotal trials in adults, rituximab was adminis-
tered on day 1 of chemotherapy. However our patients re-
ceived rituximab on day –5, to reduce the putative side-
effects and more closely monitor the outcome of therapy,
concerning the overall well-being of children, blood and
metabolic evaluation. The standard NHL-BFM95 proto-
col had to be modified, as most children developed exces-
sive fungal infections of oral, esophageal and rectal mu-
cosa, which required prolonged antimycotic treatment
and was to that extent never observed in patients treated
with standard protocol. Therefore in children receiving
rituximab new cycles of chemotherapy were started ev-
ery 28 days instead of recommended 21 days. It remains
to be disputed, whether rituximab is responsible for such
severe clinical presentations.
Although the numbers of patients we presented in
this study are too small, we believe the results are opti-
mistic. Further trials are necessary to establish the role
of rituximab in treatment of children with CD20 positive
Non-Hodgkin’s lymphoma.
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Limfomi su tre}i naj~e{}i maligni tumor u djece i adolescenata, od ~ega na B ne-Hodgkinov (B-NHL) limfom otpada
oko 60% novodijagnosticiranih slu~ajeva. Dijagnoza B-NHL-a temelji se na morfolo{koj analizi, imunofenotipizaciji,
citogenetskoj analizi i na molekularnoj genetici. Bitan napredak u lije~enju B-NHL-a u odraslih postignut je dodava-
njem rituximaba uz protokol CHOP nakon ~ega je do{lo do pobolj{anja pre`ivljenja za oko 19%. Rituximab je kimeri~no
monoklonsko protutijelo koje se ve`e za CD20, transmembranski receptor koji se nalazi na normalim i malignim B
limfocitima i ima citotoksi~ni, proapoptoti~ki i antiproliferativni u~inak. U~inak rituximaba u djece jo{ je uvijek ne-
poznanica. Temeljem analize uzoraka tkiva kod sedmero djece postavljena je dijagnoza B-NHL-a. Svi su lije~eni u na{oj
ustanovi prema protokolu lije~enja B-NHL-BFM 95 sa dodatkom rituximaba koji je primjenjen pet dana prije po~etka
kemoterapije. Kompletna remisija je postignuta u svih sedam pacijenata. [estero pacijenata se jo{ uvijek nalazi u kom-
pletnoj remisiji najmanje 12 mjeseci od prestanka lije~enja. Jedan pacijent je dobio relaps dva mjeseca po prestanku
terapije i kasnije umro. Glavne ne`eljene nuspojave terapije bile su produljeni nedostatak B limfocita i produljeno
potiskivanje rada ko{tane sr`i. Cjelokupno gledaju}i djeca su dobro podnosila rituximab sa protokolom B-NHL-BFM-
-95. Broj pacijenata u ovom radu je premali i za kona~ne zaklju~ke bit }e potrebno pra}enje ve}e skupine pacijenata.
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